Baxter International Inc
BAX: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $72.00 | Bztqgd | Dlkyyfkj |
Baxter's Kidney Care Spinoff May Face Challenges From Obesity Drug Expansion
/s3.amazonaws.com/arc-authors/morningstar/27df33e4-c5eb-4dc8-805e-babc7c688b65.jpg)
Business Strategy and Outlook
Following the spinoff of Baxalta in mid-2015, Baxter's new management team has focused on increasing efficiencies and innovating in medical products, which resulted in much-improved profitability and cash flow generation. But in 2022-23, management has faced significant external challenges and internal execution issues that, in our opinion, have caused Baxter's results to fall substantially.